- Home
- NUAI vs RIGL Comparison
NUAI vs RIGL Comparison
Compare NUAI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUAI | RIGL |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.1M | 564.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NUAI | RIGL |
|---|---|---|
| Price | $6.74 | $36.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $11.00 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 8.3M | 329.2K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $74.80 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $0.32 | $18.14 |
| 52 Week High | $9.45 | $52.24 |
Technical Indicators
Market Signals| Indicator | NUAI | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 69.98 | 73.42 |
| Support Level | $3.71 | $33.39 |
| Resistance Level | $7.59 | $36.95 |
| Average True Range (ATR) | 0.72 | 1.51 |
| MACD | 0.15 | 0.46 |
| Stochastic Oscillator | 87.33 | 97.03 |
Price Performance
Historical ComparisonAbout NUAI New Era Energy & Digital Inc.
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.